Scientists think there is one cause behind worrying rise of lung cancer in people that have never smoked
Scientists believe that air pollution could be a major cause behind the rise in global lung cancer cases in people that have ...
Lung cancer on the rise among ‘never smokers’ – 9 signs to spot the ‘silent killer’
THE proportion of people diagnosed with lung cancer who’ve never smoked is increasing, the World Health Organization (WHO) ...
Healthline6d
How Does Lung Cancer Affect Appetite? 13 Tips to Combat Weight Loss
Many people with lung cancer develop anemia, especially after chemotherapy treatment. Anemia occurs when your red blood cell levels drop too low. In one 2021 study, about 32% of the people with ...
Morningstar10d
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Small-cell lung cancer: ESMO Clinical Practice Guidelines ... is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China, the EU and several SEA countries.
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
‘It’s working!’ Columbus cancer center is first in Georgia to administer this new therapy
John B. Amos Cancer Center at Piedmont Columbus Regional ’s midtown medical complex is the first in Georgia to offer this ...
Cure Today8d
Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...
PMLiVE12d
J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...